Preclinical Formulation for the Pharmacokinetics and Efficacy of GBO-006, a Selective Polo Like Kinase 2 (PLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer. ADMET DMPK 2016, 4 (4), 314-326. https://doi.org/10.5599/admet.4.4.341.